Elanco presents Zenrelia study showing similar serologic response; approved in Canada

Elanco Animal Health Inc

Study presented at ISCAID: 68 beagles given ilunocitinib at 1X or 3X label dose for 56 days; protective titer levels post-booster similar to control group.
No serious adverse events observed; supports safety of Zenrelia concurrent with core booster vaccinations including rabies.
Zenrelia (ilunocitinib) received regulatory approval in Canada; further details on Health Canada Drug Product Database.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.